- Home
- PRME vs ABUS Comparison
PRME vs ABUS Comparison
Compare PRME & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | ABUS |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.1M | 848.1M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRME | ABUS |
|---|---|---|
| Price | $4.16 | $4.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $9.31 | $5.00 |
| AVG Volume (30 Days) | ★ 3.7M | 1.1M |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,977,000.00 | ★ $14,606,000.00 |
| Revenue This Year | $111.80 | $125.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 647.13 | 116.64 |
| 52 Week Low | $1.11 | $2.71 |
| 52 Week High | $6.94 | $5.10 |
Technical Indicators
Market Signals| Indicator | PRME | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 60.87 |
| Support Level | $3.95 | $4.43 |
| Resistance Level | $4.42 | $4.63 |
| Average True Range (ATR) | 0.30 | 0.19 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 76.72 | 89.66 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.